{"id":"https://genegraph.clinicalgenome.org/r/79862a86-a978-40c0-bc3c-591868d6bc73v1.0","type":"EvidenceStrengthAssertion","dc:description":"*UNC93B1* encodes an endoplasmic reticulum (ER) transmembrane protein involved in Toll-like receptor (TLR) trafficking from the ER to the endosomes. UNC93B1 recruits Syntenin-1 to its C-terminal end, where Syntenin-1 functions to inhibit TLR signaling. Variants in *UNC93B1* were first reported in relation to SLE in 2024 (PMIDs: 38207055, 38780621, 38831104, 38869500). \n\nGenetic evidence includes five missense variants and one in-frame insertion variant reported in six probands in four publications (PMIDs: 38207055, 38207015, 38780621, 38869500). Two and four of the variants were identified in a homozygous and heterozygous state, respectively, in the affected individuals. A case-control study using single-variant analysis for *UNC93B1* reported an odds ratio of 17.9 for developing SLE (PMID: 38831104). \n\nExperimental data includes evidence that *UNC93B1* variants reported in patients increase TLR7 signaling. Direct protein-protein interactions of UNC93B1 with TLR7 and Syntenin-1 were confirmed (PMIDs: 19451267, 31546246). Mouse models introducing *UNC93B1* variants known to cause upregulated TLR7 signaling resulted in multi-organ inflammation, glomerular disease, and positive autoantibodies (PMIDs: 38780621, 31546246, 38831104).\n\nIn summary, there is **moderate** evidence supporting the relationship between variants of *UNC93B1* and a semidominant phenotype of Systemic Lupus Erythematosus. This classification was approved by the ClinGen Monogenic Systemic and Incomplete Lupus Erythematosus GCEP on the meeting date April 9, 2025 (SOP Version 11).\n\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/79862a86-a978-40c0-bc3c-591868d6bc73","GCISnapshot":"https://genegraph.clinicalgenome.org/r/5cd5e1c8-5047-4ea1-9045-cb5bf978613b","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/5cd5e1c8-5047-4ea1-9045-cb5bf978613b_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10123","date":"2025-04-09T19:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/5cd5e1c8-5047-4ea1-9045-cb5bf978613b_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10123","date":"2025-09-12T00:27:52.997Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5cd5e1c8-5047-4ea1-9045-cb5bf978613b_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5cd5e1c8-5047-4ea1-9045-cb5bf978613b_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/613fbab0-3ead-4dc9-92ac-f36ce96a07bd","type":"EvidenceLine","dc:description":"Score downgraded from 2 to 0.5 because the same paper was used to score the case-control series above as well as because the mouse data is weak and not clearly specific to SLE inflammation. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/44f023d9-5afb-4b3a-8e8e-90d02655cbfa","type":"Finding","dc:description":" UNC93B1V117L drives increased inflammation and TLR7 responses in mice; increased IFN signaling.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38831104","rdfs:label":"Mouse Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fd4b4337-1d23-496d-8958-519bebee4b5b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a431205a-affc-48d3-a6ff-2f9059a4dceb","type":"Finding","dc:description":"Development of increased TLR7 signaling, Development of increased ABCs/Plasma Cells / ANA antibodies, glomerulonephritis. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38780621","rdfs:label":"Mutagenesis screen and Mouse Models","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/5cd5e1c8-5047-4ea1-9045-cb5bf978613b_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2629ee4a-fd9e-4aea-b8d2-77e67cc3a34f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6839789-a195-4d93-a772-55198da92280","type":"Finding","dc:description":"The N-terminal portion of UNC93B1 repressed TLR7 responses. Mutations that truncate the N terminal enable TLR7 responses.  Evidence of co-immunoprecipitation and direct interaction are shown in Figure 5.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19451267","rdfs:label":"Fukui et al.","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/62655dd4-fcc1-4771-9789-34f63d7f9976","type":"EvidenceLine","dc:description":"The paper was not just about protein interaction but also a mouse model with UNC93B1 mutations where mice developed +ANA, autoimmunity, systemic inflammation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/525a9472-c990-474b-bf33-d66898361cb3","type":"Finding","dc:description":"The C-terminal tail of UNC93B1 binds Syntenin-1, this restricts TLR7 signaling. \nUNC93B1 mutated mice develop systemic inflammation and autoimmunity, + ANA.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31546246","rdfs:label":"UNC93B1 recruits syntenin-1 to dampen TLR7 signaling.","demonstrates":{"id":"obo:MI_0933"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.75}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.25}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.75},{"id":"https://genegraph.clinicalgenome.org/r/5cd5e1c8-5047-4ea1-9045-cb5bf978613b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5cd5e1c8-5047-4ea1-9045-cb5bf978613b_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c9b11755-ee6e-4099-8fe8-d3603a43fc87_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38869500","rdfs:label":"AGS2898","family":{"id":"https://genegraph.clinicalgenome.org/r/c9b11755-ee6e-4099-8fe8-d3603a43fc87","type":"Family","rdfs:label":"AGS2898","member":{"id":"https://genegraph.clinicalgenome.org/r/42d5c7e1-52b4-46c9-93dc-c6c0a50a49a1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38869500","rdfs:label":"P2","allele":{"id":"https://genegraph.clinicalgenome.org/r/b5d8815e-fa69-4eac-bd00-3a0bdf7c3750","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_030930.4(UNC93B1):c.973G>T (p.Gly325Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381572819"}},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"early onset SLE; no clinical information is available","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/733276b3-0bbe-480a-885d-5055c6290032_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38869500","allele":{"id":"https://genegraph.clinicalgenome.org/r/b5d8815e-fa69-4eac-bd00-3a0bdf7c3750"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Semidominant"},"phenotypeFreeText":"early onset SLE; no clinical information is available","proband":{"id":"https://genegraph.clinicalgenome.org/r/42d5c7e1-52b4-46c9-93dc-c6c0a50a49a1"}},{"id":"https://genegraph.clinicalgenome.org/r/ac7875f1-84e2-44af-854a-da9e9b2785cf_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38869500","rdfs:label":"AGS2650","family":{"id":"https://genegraph.clinicalgenome.org/r/ac7875f1-84e2-44af-854a-da9e9b2785cf","type":"Family","rdfs:label":"AGS2650","member":{"id":"https://genegraph.clinicalgenome.org/r/71af1f3c-9e71-4730-b49e-d2336b8049fd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38869500","rdfs:label":"I317M","allele":{"id":"https://genegraph.clinicalgenome.org/r/9178c494-2c50-43a9-bd9d-9bacf807a4d6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_030930.4(UNC93B1):c.951C>G (p.Ile317Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381573023"}},"detectionMethod":"searched for very rare, that is, a minor allele frequency below 10−5, in-frame and out-of-frame variants in protein coding exons, in the exome sequence data of patients with a molecularly uncharacterized diagnosis of systemic SLE or chillblain, ","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"clinically diagnosed with early onset SLE","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ef19775f-a8f8-4fcf-bc69-8d94f17156d1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38869500","allele":{"id":"https://genegraph.clinicalgenome.org/r/9178c494-2c50-43a9-bd9d-9bacf807a4d6"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:BiallelicHomozygous"}},"zygosity":{"id":"cg:BiallelicHomozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"phenotypeFreeText":"clinically diagnosed with early onset SLE","phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/71af1f3c-9e71-4730-b49e-d2336b8049fd"}},{"id":"https://genegraph.clinicalgenome.org/r/072b459a-65ec-4723-95df-0b17fae28fb1_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38207055","rdfs:label":"Family A","family":{"id":"https://genegraph.clinicalgenome.org/r/072b459a-65ec-4723-95df-0b17fae28fb1","type":"Family","rdfs:label":"Family A","member":{"id":"https://genegraph.clinicalgenome.org/r/c56e5756-99c4-4e72-b753-a4ec079bb8c4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38207055","rdfs:label":"Wolf_P1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/bde1804d-84b0-4415-8ac3-9976006e4210","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_030930.4(UNC93B1):c.275A>G (p.Glu92Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381578451"}},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Patient 1 developed first symptoms of SLE at 4 months of age, including refractory autoimmune thrombocytopenia, autoimmune anemia, and erythematous rash, \nfollowed by hepatosplenomegaly, glomerulonephritis, arthritis, \nand panniculitis over the following 6 years.  + ANA and + anti-dsDNA.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e7610e3a-13cb-4b60-9252-f600be7ff170_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38207055","allele":{"id":"https://genegraph.clinicalgenome.org/r/bde1804d-84b0-4415-8ac3-9976006e4210"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:BiallelicHomozygous"}},"zygosity":{"id":"cg:BiallelicHomozygous"}},"cg:modeOfInheritance":"Autosomal recessive"},"phenotypeFreeText":"Patient 1: Autoimmune thrombocytopenia, anemia, rash, glomerulonephritis, arthritis, panniculitis, ANA, anti-dsDNA\nPatient 2:  Anemia, malar rash, renal disease, vasculitis, seizure, ANA, anti-dsDNA","phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/c56e5756-99c4-4e72-b753-a4ec079bb8c4"}},{"id":"https://genegraph.clinicalgenome.org/r/ab38475a-c126-4074-aa79-0bde7d205624_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38207055","rdfs:label":"Family B","family":{"id":"https://genegraph.clinicalgenome.org/r/ab38475a-c126-4074-aa79-0bde7d205624","type":"Family","rdfs:label":"Family B","member":{"id":"https://genegraph.clinicalgenome.org/r/1fb863ed-da75-47de-9303-644c9d966dbb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38207055","rdfs:label":"Wolf_P3_proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/186d985b-27b8-4ab0-b91a-784e69eeb9f0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_030930.4(UNC93B1):c.1007G>T (p.Arg336Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381572550"}},"phenotypeFreeText":"first signs of SLE at 18 months of age, including dermatitis, positive ANAs, and hypocomplementemia.  At 16 years, he developed hepatomegaly, progressive generalized \nlymphadenopathy, and arthralgia. At 19 years, he was noted to have proteinuria, hyperglobulinemia, anti–β2-glycoprotein, and anti-dsDNA antibodies ","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1e5e8512-561b-43f9-9ad3-06e7971abd56_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38207055","allele":{"id":"https://genegraph.clinicalgenome.org/r/186d985b-27b8-4ab0-b91a-784e69eeb9f0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/1fb863ed-da75-47de-9303-644c9d966dbb"}},{"id":"https://genegraph.clinicalgenome.org/r/4429a778-f1f5-4f46-ac75-45502d59fcab_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38207015","rdfs:label":"5A","family":{"id":"https://genegraph.clinicalgenome.org/r/4429a778-f1f5-4f46-ac75-45502d59fcab","type":"Family","rdfs:label":"5A","member":{"id":"https://genegraph.clinicalgenome.org/r/b1e79cde-4900-4963-b609-4fbb4955f19b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38207015","rdfs:label":"IL3","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":7,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e1704428-396d-4177-9d42-978288a1e188","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_030930.4(UNC93B1):c.145_147dup (p.Glu49dup)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA600238104"}},"detectionMethod":"\"No other structural or sequence gene variants associated with SLE were identified in the patient genome\"","phenotypeFreeText":"Starting from age of 7: atopic dermatitis, sialadenitis, generalized lymphadenopathy, splenomegaly. +ANA, leukopenia, low complements, hyper IgG.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/abc029fc-8901-4ccd-ba62-6712379416ff_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38207015","allele":{"id":"https://genegraph.clinicalgenome.org/r/e1704428-396d-4177-9d42-978288a1e188"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Semidominant"},"phenotypeFreeText":"Starting from age of 7: atopic dermatitis, sialadenitis, generalized lymphadenopathy, splenomegaly. +ANA, leukopenia, low complements, hyper IgG.","proband":{"id":"https://genegraph.clinicalgenome.org/r/b1e79cde-4900-4963-b609-4fbb4955f19b"}},{"id":"https://genegraph.clinicalgenome.org/r/709a3081-99a3-44c9-bc52-9d3ee4e63bea_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38780621","rdfs:label":"Rael AIII","family":{"id":"https://genegraph.clinicalgenome.org/r/709a3081-99a3-44c9-bc52-9d3ee4e63bea","type":"Family","rdfs:label":"Rael AIII","member":{"id":"https://genegraph.clinicalgenome.org/r/5d6e1ff5-6c66-4ea0-bf04-99467d2b05d4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38780621","rdfs:label":"AIII.1","allele":{"id":"https://genegraph.clinicalgenome.org/r/48ac7b84-10c6-4f27-8ae5-e639ec99d7df","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_030930.4(UNC93B1):c.278C>T (p.Thr93Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381578430"}},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"early-childhood onset cutaneous tumid lupus, with no symptoms of systemic lupus","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/389b9302-1903-4f2d-9a2d-bd13b88c064b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38780621","allele":{"id":"https://genegraph.clinicalgenome.org/r/48ac7b84-10c6-4f27-8ae5-e639ec99d7df"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}},"phenotypeFreeText":"cutaneous tumid lupus","phenotypePositiveAllelePositive":4,"proband":{"id":"https://genegraph.clinicalgenome.org/r/5d6e1ff5-6c66-4ea0-bf04-99467d2b05d4"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/42d5c7e1-52b4-46c9-93dc-c6c0a50a49a1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/733276b3-0bbe-480a-885d-5055c6290032","type":"EvidenceLine","dc:description":"Asymptomatic mother carries same the variant, but has similar molecular phenotype (higher TLR signaling).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/733276b3-0bbe-480a-885d-5055c6290032_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The G325C variant demonstrated an equivalent TLR7-enhancing effect. \n The G325C variant induced a higher NF-κB response.\n\nAdditionally, ex-vivo stimulation with TLR7 and TLR8 agonists induced greater TNF and IFNa release in the G325C PBMC and monocyte cells vs. WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/733276b3-0bbe-480a-885d-5055c6290032_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/42d5c7e1-52b4-46c9-93dc-c6c0a50a49a1"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/71af1f3c-9e71-4730-b49e-d2336b8049fd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef19775f-a8f8-4fcf-bc69-8d94f17156d1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef19775f-a8f8-4fcf-bc69-8d94f17156d1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NF-κB activity increases following specifically TLR7 stimulation of TLR-knock out HEK293T cells transfected with TLR7 and the variant UNC93B1, compared to cells transfected with other TLR or WT UNC93B1 function. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ef19775f-a8f8-4fcf-bc69-8d94f17156d1_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/71af1f3c-9e71-4730-b49e-d2336b8049fd"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5cd5e1c8-5047-4ea1-9045-cb5bf978613b_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/faee090f-5321-4494-b8f4-7ff9977a8a38","type":"EvidenceLine","dc:description":"There is very little information provided about the Controls, other than demographic information.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/faee090f-5321-4494-b8f4-7ff9977a8a38_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38831104","rdfs:label":"SLE vs. South-East China Han","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/5947743f-466d-4f02-91f2-d50774e6f60a","type":"Cohort","allGenotypedSequenced":272,"alleleFrequency":0.02573529411764706,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/faee090f-5321-4494-b8f4-7ff9977a8a38_cc_evidence_item"}],"numWithVariant":7,"relatedCondition":{"id":"obo:MONDO_0007915"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/ce3d9971-2e95-420c-8453-24a20bae8e21","type":"Cohort","allGenotypedSequenced":4063,"alleleFrequency":0.001476741324144721,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/faee090f-5321-4494-b8f4-7ff9977a8a38_cc_evidence_item"}],"numWithVariant":6},"lowerConfidenceLimit":6.54,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":0.0000040,"statisticalSignificanceType":"","statisticalSignificanceValue":17.9,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":53.5}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/b1e79cde-4900-4963-b609-4fbb4955f19b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/abc029fc-8901-4ccd-ba62-6712379416ff","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/abc029fc-8901-4ccd-ba62-6712379416ff_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The variant was associated with a gain of function TLR signaling.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/abc029fc-8901-4ccd-ba62-6712379416ff_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b1e79cde-4900-4963-b609-4fbb4955f19b"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c56e5756-99c4-4e72-b753-a4ec079bb8c4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e7610e3a-13cb-4b60-9252-f600be7ff170","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e7610e3a-13cb-4b60-9252-f600be7ff170_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"P1 had a high resting PBMC IFN score.  Following whole-blood stimulation with a TLR7 agonist, increased levels of IL6, IL1B, TNFa were seen from P1 as compared to controls. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e7610e3a-13cb-4b60-9252-f600be7ff170_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c56e5756-99c4-4e72-b753-a4ec079bb8c4"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5d6e1ff5-6c66-4ea0-bf04-99467d2b05d4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/389b9302-1903-4f2d-9a2d-bd13b88c064b","type":"EvidenceLine","dc:description":"1. This was cutaneous chillblain lupus, not systemic disease. The authors specifically looked for the UNC93B1 mutation, not taking into account any other mutations the family may have.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/389b9302-1903-4f2d-9a2d-bd13b88c064b_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/5d6e1ff5-6c66-4ea0-bf04-99467d2b05d4"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1fb863ed-da75-47de-9303-644c9d966dbb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e5e8512-561b-43f9-9ad3-06e7971abd56","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e5e8512-561b-43f9-9ad3-06e7971abd56_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/1fb863ed-da75-47de-9303-644c9d966dbb"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":5.7}],"evidenceStrength":"Moderate","sequence":11673,"specifiedBy":"GeneValidityCriteria11","strengthScore":9.45,"subject":{"id":"https://genegraph.clinicalgenome.org/r/GvaKSgsHf_c","type":"GeneValidityProposition","disease":"obo:MONDO_0007915","gene":"hgnc:13481","modeOfInheritance":"obo:HP_0032113"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_5cd5e1c8-5047-4ea1-9045-cb5bf978613b-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}